Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: A retrospective cohort study

Endocrine Journal

Volumn 62, Issue 11, 2015, Pages 971-980

  Kondo, Yoshinobu ^a,b   Satoh, Shinobu ^b   Osada, Uru Nezu ^c   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b CHIGASAKI MUNICIPAL HOSPITAL   (Japan)

^c Department of Urology   (Japan)

Author keywords

Diabetes duration; Early treatment; Liraglutide; Type 2 diabetes; cell function

Indexed keywords

C PEPTIDE; GLUCAGON; INSULIN; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DRUG DOSE TITRATION; EARLY INTERVENTION; FEMALE; GLYCEMIC CONTROL; HUMAN; IMMUNOREACTIVITY; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PROVOCATION TEST; RETROSPECTIVE STUDY; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED;

AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; LIRAGLUTIDE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84948969329     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ15-0206     Document Type: Article

References (50)

1. U. K. Prospective Diabetes Study Group (1995) U. K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease. Diabetes 44: 1249-1258.
2. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G (2000) Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 37: 125-129.
3. Bo S, Gentile L, Castiglione A, Prandi V, Canil S, et al. (2012) C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. Eur J Endocrinol 167: 173-180.
4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, et al. (2003) Beta-cell deficit and increased betacell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110.
5. Butler AE, Janson J, Soeller WC, Butler PC (2003) Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52: 2304-2314.
6. Blonde L, Russell-Jones D (2009) The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 11 Suppl 3: 26-34.
7. Kozawa J, Inoue K, Iwamoto R, Kurashiki Y, Okauchi Y, et al. (2012) Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin secreting capacity. J Diabetes Investig 3: 294-297.
8. Iwao T, Sakai K, Sata M (2013) Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. J Diabetes Complications 27: 87-91.
9. Kondo Y, Satoh S, Nagakura J, Kimura M, Nezu U, et al. (2013) Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. J Diabetes Investig 4: 571-575.
10. Usui R, Yabe D, Kuwata H, Fujiwara S, Watanabe K, et al. (2013) Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function. J Diabetes Investig 4: 585-594.
11. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3: 153-165.
12. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, et al. (2003) Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets. Endocrinology 144: 5149-5158.
13. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, et al. (2004) One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and betacell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53: 1187-1194.
14. Toso C, McCall M, Emamaullee J, Merani S, Davis J, et al. (2010) Liraglutide, a long-acting human glucagonlike peptide 1 analogue, improves human islet survival in culture. Transpl Int 23: 259-265.
15. Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, et al. (2011) The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 54: 1098-1108.
16. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, et al. (2009) Efficacy and safety of the human glucagonlike peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32: 1224-1230.
17. Seino Y, Rasmussen MF, Clauson P, Kaku K (2012) The once daily human glucagon like peptide 1 analog, liraglutide, improves β cell function in Japanese patients with type 2 diabetes. J Diabetes Investig 3: 388-395.
18. Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, et al. (2008) Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 25: 152-156.
19. Takabe M, Matsuda T, Hirota Y, Hashimoto N, Nakamura T, et al. (2012) C-peptide response to glucagon glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment. Diabetes Res Clin Pract 98: e32-e35.
20. Faber OK, Binder C (1977) C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 26: 605-610.
21. Hendriksen C, Faber OK, Drejer J, Binder C (1977) Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 13: 615-619.
22. Gjessing HJ, Damsgaard EM, Matzen LE, Frøland A, Faber OK (1987) Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus. Diabetes Care 10: 558-562.
23. Kawai K, Yokota C, Ohashi S, Watanabe Y, Yamashita K (1995) Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Diabetologia 38: 274-276.
24. Meier JJ, Menge BA, Breuer TG, Müller CA, Tannapfel A, et al. (2009) Functional assessment of pancreatic beta-cell area in humans. Diabetes 58: 1595-1603.
25. Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, et al. (2011) Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. J Diabetes Investig 2: 297-303.
26. Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21: 2191-2192.
27. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, et al. (2012) International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig 3: 39-40.
28. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992.
29. American Diabetes Association (2014) Standards of medical care in diabetes-2014. Diabetes Care 37 Suppl 1: S14-S80.
30. Schuit FC (1996) Factors determining the glucose sensitivity and glucose responsiveness of pancreatic beta cells. Horm Res 46: 99-106.
31. Murao K, Li J, Imachi H, Muraoka T, Masugata H, et al. (2009) Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic beta-cell line. Diabetes Obes Metab 11: 939-946.
32. Shirakawa J, Tanami R, Togashi Y, Tajima K, Orime K, et al. (2012) Effects of liraglutide on β-cell-specific glucokinase-deficient neonatal mice. Endocrinology 153: 3066-3075.
33. Weng J, Li Y, Xu W, Shi L, Zhang Q, et al. (2008) Effect of intensive insulin therapy on β-cell function and gly caemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371: 1753-1760.
34. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, et al. (2008) Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 31: 1927-1932.
35. Hu Y, Li L, Xu Y, Yu T, Tong G, et al. (2011) Shortterm intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission. Diabetes Care 34: 1848-1853.
36. Owens DR (2013) Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther 15: 776-785.
37. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, et al. (2009) One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32: 762-768.
38. Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, et al. (2011) Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34: 2041-2047.
39. Xu W, Bi Y, Sun Z, Li J, Guo L, et al. (2015) Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). J Intern Med 277: 137-150.
40. Shao Y, Yuan G, Feng Y, Zhang J, Guo X (2014) Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice. Peptides 52: 134-142.
41. D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, et al. (2006) Production of pancreatic hormoneexpressing endocrine cells from human embryonic stem cells. Nat Biotechnol 24: 1392-1401.
42. Parnaud G, Bosco D, Berney T, Pattou F, Kerr-Conte J, et al. (2008) Proliferation of sorted human and rat beta cells. Diabetologia 51: 91-100.
43. Utzschneider KM, Carr DB, Barsness SM, Kahn SE, Schwartz RS (2004) Diet-induced weight loss is associated with an improvement in beta-cell function in older men. J Clin Endocrinol Metab 89: 2704-2710.
44. Solomon TP, Haus JM, Kelly KR, Rocco M, Kashyap SR, et al. (2010) Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide. Diabetes Care 33: 1561-1566.
45. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, et al. (2012) The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 95: e20-e22.
46. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54: 10-18.
47. Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B (2014) Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 37: 3270-3278.
48. Ohta A, Kato H, Murayama K, Hashimoto E, Murakami M, et al. (2014) Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs. Endocr J 61: 13-18.
49. Pistrosch F, Köhler C, Schaper F, Landgraf W, Forst T, et al. (2013) Effects of insulin glargine versus metformin on glycemic variability, microvascular and betacell function in early type 2 diabetes. Acta Diabetol 50: 587-595.
50. Bi Y, Tong GY, Yang HJ, Cai MY, Ma JH, et al. (2013) The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev 29: 664-672.